This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with
moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled,
parallel group study. Pharmacokinetics of KHK4827 will also be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.